Advertisement
UK markets close in 4 hours 7 minutes
  • FTSE 100

    8,089.13
    +48.75 (+0.61%)
     
  • FTSE 250

    19,698.85
    -20.52 (-0.10%)
     
  • AIM

    754.76
    +0.07 (+0.01%)
     
  • GBP/EUR

    1.1663
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.2512
    +0.0050 (+0.40%)
     
  • Bitcoin GBP

    50,941.32
    -2,146.97 (-4.04%)
     
  • CMC Crypto 200

    1,350.71
    -31.86 (-2.31%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     
  • GOLD FUTURES

    2,340.90
    +2.50 (+0.11%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,952.55
    -136.15 (-0.75%)
     
  • CAC 40

    8,017.21
    -74.65 (-0.92%)
     

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

Emergent BioSolutions
Emergent BioSolutions

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

ADVERTISEMENT

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedInX (formerly Twitter), and Instagram.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com